Xcorporeal (Xcorporeal) Interest Expense : $0.00 Mil (TTM As of Sep. 2009)

View and export this data going back to . Start your Free Trial

What is Xcorporeal Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Xcorporeal's interest expense for the three months ended in Sep. 2009 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2009 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Xcorporeal's Operating Income for the three months ended in Sep. 2009 was $ -1.54 Mil. Xcorporeal's Interest Expense for the three months ended in Sep. 2009 was $ 0.00 Mil. Xcorporeal has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Xcorporeal Interest Expense Historical Data

The historical data trend for Xcorporeal's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xcorporeal Interest Expense Chart

Xcorporeal Annual Data

Trend

Feb99

Feb00

Dec01

Dec02

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Interest Expense

Get a 7-Day Free Trial

Xcorporeal Quarterly Data
	Dec04	Mar05	Jun05	Sep05	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Xcorporeal Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2009 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Xcorporeal (GREY:XCRP) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Xcorporeal's Interest Expense for the three months ended in Sep. 2009 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2009 was $-1.54 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2009 was $0.00 Mil.

Xcorporeal's Interest Coverage for the quarter that ended in Sep. 2009 is calculated as

Xcorporeal had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Xcorporeal (Xcorporeal) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xcorporeal Inc (GREY:XCRP) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

80 Empire Drive, Lake Forest, CA, USA, 92630

Website

Xcorporeal Inc is a medical device company, developing an innovative extra-corporeal platform technology to be used in devices to replace the function of various human organs.

Executives

Kelly J. Mccrann	director, officer: Chairman and CEO	11150 SANTA MONICA BLVD #1500, LOS ANGELES CA 90025
Daniel S Goldberger	officer: Chief Executive Officer	24 CARPENTER ROAD, CHESTER NY 10918
Marc G Cummins	director	C/O PRIME LOGIC CAPITAL, LLC, 135 EAST 57TH STREET, 11TH FLOOR, NEW YORK NY 10022
Prime Logic Capital, Llc	10 percent owner	135 EAST 57TH STREET, 11TH FLOOR, NEW YORK NY 10022
Robert Weinstein	officer: Chief Financial Officer	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Terren S Peizer	director, 10 percent owner, officer: Executive Chairman	11111 SANTA MONICABLVD STE.500, LOS ANGELES CA 90025
Jay Wolf	director	981 LINDA FLORA DRIVE, LOS ANGELES, CA 90049
Herve De Kergrohen	director	22 CHEMIN DU NANTET, COLLONGE-BELLERIVE V8 CH1245
Nicholas Sheridan Lewin	director	3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Lawrence Lacerte	10 percent owner	C/O TERAGLOBAL COMMUNICATIONS CORP, 9171 TOWNE CENTRE DRIVE SUITE 600, SAN DIEGO CA 92122